Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Scientists identify way to sensitize drug-resistant glioblastoma cells to chemotherapy

Scientists from the Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy.

20 Nov 2015

TGen: PPF drug could help treat patients with deadly brain cancer

In a significant breakthrough, the Translational Genomics Research Institute has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.

13 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies

When it comes to fending off disease and helping prevent people from falling ill, the body's immune system -- armed with T-cells that help eliminate cancer cells, virus-infected cells and more -- is second to none. But exactly how the immune system works remains, in many ways, a mystery, as there are numerous cell types whose functions and interactions with our immune systems have not been well understood.

5 Nov 2015

UCSD researchers develop new computational strategy to find tumor-shrinking molecules

Patients with glioblastoma, a type of malignant brain tumor, usually survive fewer than 15 months following diagnosis. Since there are no effective treatments for the deadly disease, University of California, San Diego researchers developed a new computational strategy to search for molecules that could be developed into glioblastoma drugs. In mouse models of human glioblastoma, one molecule they found shrank the average tumor size by half.

31 Oct 2015

RNA profiles of tumor-educated platelets may diagnose cancer, identify potential therapeutic approaches

Analysis of tumor RNA carried in platelets - blood components best known for their role in clotting - may prove to be more useful than other "liquid biopsy" technologies for diagnosing cancer and determining its primary location and potential therapeutic approaches.

31 Oct 2015

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation announced today that Franziska Michor, PhD, is the 2015 recipient of the NYSCF - Robertson Stem Cell Prize for her work pioneering new approaches to study the growth, spread, and treatment of cancer. Her laboratory fuses her passions in mathematics, molecular biology and patient care to investigate how cancers form and progress.

29 Oct 2015

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

19 Oct 2015

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

A Case Western Reserve University researcher has received a 5-year, $2.82 million National Institutes of Health grant to make, in essence, stealth bombs that slip past the brain's defenses to attack an incurable form of cancer.

15 Oct 2015

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

FDA approves expanded indication for Optune device for brain cancer patients

The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.

9 Oct 2015

Scientists map EGFRvIII mutant that causes brain cancer

A team of Ludwig Cancer Research scientists has mapped out how a mutant version of the epidermal growth factor receptor (EGFR) known as EGFRvIII specifically drives critical processes that alter the reading of the genome to fuel the growth of the brain cancer glioblastoma multiforme (GBM) and--most important--how each process is linked to the other.

9 Oct 2015

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

A rabbit virus currently being developed for cancer therapy can be paired with one of several existing drugs to deliver a more potent punch to a deadly type of brain tumor cell, researchers have found.

7 Oct 2015

Researchers discover five new genetic variants associated with brain cancer

The biggest ever study of DNA from people with glioma - the most common form of brain cancer - has discovered five new genetic variants associated with the disease.

1 Oct 2015

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Monteris Medical today announced recent data demonstrating that newly diagnosed brain tumor patients undergoing procedures with the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool, experienced improved outcomes.

1 Oct 2015

Innovative way may stop spread of glioblastoma multiforme

Scientists at the University of Toledo Health Science Campus and Van Andel Research Institute have discovered an innovative way that may stop the spread of the most lethal and aggressive brain cancer glioblastoma multiforme (GBM). In laboratory studies, scientists demonstrated that activating a specific family of proteins halted cancer cell migration into healthy tissue.

22 Sep 2015

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.

10 Sep 2015

Innovative vaccine therapy shows promise against glioblastoma brain tumors

An innovative vaccine therapy developed at Roswell Park Cancer Institute is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The phase II study, now accruing patients at both Roswell Park and the Cleveland Clinic, will assess the effectiveness of the SurVaxM vaccine in combination with standard chemotherapy as treatment for this often-fatal cancer.

10 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

UCLA scientists develop promising new combination treatment for glioblastoma

UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the deadliest form of brain cancer.

2 Sep 2015